High Or low dose Syntocinon® for delay in labour
| ISRCTN | ISRCTN99841044 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN99841044 |
| EudraCT/CTIS number | 2015-005537-50 |
| Secondary identifying numbers | v2.0; HTA Project: 14/140/44 |
- Submission date
- 11/07/2016
- Registration date
- 03/08/2016
- Last edited
- 20/09/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Plain English Summary
Background and study aims
It is not currently known what the best care for first time mothers with delayed progress in the first stage of labour is. This topic is a research priority for the Royal College of Obstetricians and Gynaecologists. Delayed labour is relatively common, affecting between 11- 30% (equivalent to between one and three in ten) of first time mothers. The only recommended treatment is artificial oxytocin (Syntocinon®) which is given intravenously (through the vein) to stimulate contractions. A standard regimen (concentration and rate of administration) is recommended by NICE Guidelines 2014 and is widely used in the UK. Information from studies looking at different dose regimens of Syntocinon ® for delayed labour suggest that a high dose regimen may reduce the chance of Caesarean section but the available evidence is not conclusive. Syntocinon ® may cause the uterus to contract too much and the baby to become distressed so both mother and baby are carefully monitored and the dose adjusted in relation to the number of contractions and how the baby is. Research shows currently around 32% (equivalent to about three in ten) of the women who need Syntocinon® for delayed labour have an unplanned Caesarean section , which is related to a longer hospital stay, higher risk of infection, bleeding and blood clots and to increase risk of Caesarean section being required in future pregnancies. By reducing the number of Caesarean sections, these risks can also be reduced. A reduction in the Caesarean section rate of 5-8% (equivalent to nearly one in ten) in these women could save the NHS nearly £1M per year, as well as possible annual savings of £2.6M from the impact of avoiding Caesarean section in future pregnancies. The study is looking at whether treatment with a high dose of Syntocinon® reduces the need for Caesarean section in women with delayed labour.
Who can participate?
Women having their first baby and confirmed as being in delayed labour.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in group 1 are treated with the standard dose of oxytocin. Those in group 2 are treated with a high dose of oxytocin, which is double the concentration of the standard dose. All participants from both groups are followed to see, for example, whether they have to have a caesarean section, have an epidural during the labour, how long each of the three stages of labour takes and how long the birth takes altogether.
What are the possible benefits and risks of participating?
Syntocinon ® may cause the uterus to contract too much and the baby to become distressed so both mother and baby are carefully monitored and the dose adjusted in relation to the number of contractions and how the baby is.
Where is the study run from?
Birmingham Womens NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
March 2016 to May 2019
Who is funding the study?
NIHR Health Technology Assessment Programme, HTA (UK)
Who is the main contact?
Dr Sara Kenyon
HOLDS@trials.bham.ac.uk
Contact information
Public
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
| Phone | 0121 415 8298 |
|---|---|
| HOLDS@trials.bham.ac.uk |
Study information
| Study design | Multicentre pragmatic randomized double-blind controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | No participant information sheet available at present |
| Scientific title | High Or Low Dose Syntocinon® for delay in labour: the HOLDS trial |
| Study acronym | HOLDS |
| Study hypothesis | HOLDS will provide robust evidence of clinical effectiveness of a high dose compared to the current standard dose regimen of oxytocin in reducing the need for Caesarean section (CS) for nulliparous women with confirmed delay in the first stage of labour. |
| Ethics approval(s) | West Midlands - Edgbaston Research Ethics Committee, 24/02/2016, ref: 16/WM/0014 |
| Condition | Nulliparous women with a singleton cephalic pregnancy at term (37-42 weeks gestation) with confirmed delay in labour and ruptured membranes as defined by NICE Intrapartum Care Guidelines for whom the clinical decision has been made to prescribe Syntocinon for augmentation of labour. |
| Intervention | HOLDS is a double- blinded randomised controlled trial which will compare the standard dose regimen of oxytocin with a high dose regimen. NICE guidance recommends a standard dose regimen of oxytocin (2mU/min increasing every 30 minutes to a maximum 32mU/min). The comparator is high dose regimen (4mU/min increasing every 30 minutes to a maximum of 64mU/min). The high dose regimen ( i.e. double the concentration) has a higher starting dose, earlier attainment of conventional maximum doses (at 2 hours rather than over 4 hours) and the possible use of higher maximum doses of oxytocin compared to the standard regimen. Once delay in labour is confirmed women will be randomised to the standard dose will receive a solution containing 2 x 5iu ampoules in 50mls or 500mls and those to the high dose a solution containing 2 x 10iu in 50 mls or 500mls. Ampoules are manufactured as 5 and 10 iu and these regimens have been selected to enable the trial to be double-blinded. Intervention will last for the remainder of the first stage and until completion of the second stage of labour. Data will be collected by the research midwife through CRFs (i.e., labour, birth and discharge and a neonatal CRFs) from clinical data routinely recorded. Data collection will start after the participant has given consent and end at discharge from hospital. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Syntocinon (Oxytocin) |
| Primary outcome measure | Incidence of caesarean section, data taken from medical notes |
| Secondary outcome measures | 1. Incidence of epidural use during labour 2. Duration of first, second and third stages of labour 3. Time to birth from randomisation 4. Prevalence of mode of birth (spontaneous vaginal birth (SVB), instrumental or caesarean section) 5. Degree of perineal trauma (first, second, third and fourth) 6. Reason for caesarean section and decision to delivery interval for CS 7. Confirmed urinary retention requiring catheterisation and pulmonary oedema 8. Tachysystole (uterine contractions greater than 5 in 10 mins for 20 minutes) requiring reduction in oxytocin and/or tocolysis 9. Hyperstimulation (uterine contractions greater than 5 in 10 mins for 20 minutes resulting in non-ressurring or abnormal fetal heart rate) 10. Fetal blood sampling (FBS) during labour or significant STAN event (for those Units that use ST waveform analysis for intrapartum fetal monitoring) 11. Abnormal cardiotocogram leading to immediate birth without fetal blood sample 12. Incidence of maternal morbidity (anaphylaxis, pulmonary oedema, postpartum haemorrhage, shoulder dystocia, chorioamnioitis, uterine rupture/hysterectomy) 13. Active management of third stage of labour 14. Length of time after birth in hospital [days] 15. Admission to HDU/ITU 16. Maternal death 17. Time from randomisation to commencement of allocation 18. Total oxytocin dose 19. Time to maximum oxytocin rate 20. Maximum oxytocin dose reached 21. Gender and birthweight of neonate 22. Apgar score at 5 minutes 23. Arterial cord blood gases when collected 24. Breastfeeding rates on discharge from hospital 25. Length of time after birth in hospital [days] 26. Incidence of need to resuscitate neonate 27. Reason for neonatal review on ward (excluding routine baby check) 28. Reason for admission to neonatal unit (NNU) and level of care received (level 1,2,3) including intensive care 29. Duration of respiratory support for neonate 30. Number of days to full oral feeds 31. Incidence of seizures of neonate 32. Incidence of neonatal encephalopathy ( SARNAT grade) 33. Incidence of therapeutic hypothermia (cooling) of neonate required 34. Incidence of intrapartum still birth 35. Incidence of early neonatal death (within seven days of birth) All data taken from medical notes other than outcome 18, where the data is recorded directly onto the Clinical Records Form. |
| Overall study start date | 01/03/2016 |
| Overall study end date | 31/05/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target number of participants | 1500 |
| Participant inclusion criteria | 1. Nulliparous women with singleton cephalic pregnancy at term (37-42 weeks gestation) 2. Confirmed delay in labour and ruptured membranes for whom the clinical decision has been made to prescribe Syntocinon for augmentation of labour According to NICE guidance [NICE 2014], labour is established when there are regular painful contractions and progressive cervical dilation from 4 cm. Delay is suspected when cervical dilation of < 2 cm in 4 hours occurs once labour is established. Delay is confirmed when progress of <1 cm in 2 hours is found on repeat vaginal examination. |
| Participant exclusion criteria | 1. Multiparous women 2. Nulliparous women who: 2.1. Are undergoing induction of labour 2.2. Have a BMI >40 at booking 2.3. Have a multiple pregnancy 2.4. Have existing cardiac disease, bleeding disorders, diabetes (either pre-existing or gestational), previous uterine surgery 2.5. Have had significant antepartum haemorrhage 2.6. Are under 16 years of age 2.7. Have a known contra-indication to oxytocin therapy as listed in the Summary of marketing Product Characteristics |
| Recruitment start date | 01/03/2017 |
| Recruitment end date | 31/08/2018 |
Locations
Countries of recruitment
- England
- United Kingdom
- Wales
Study participating centres
Edgbaston
Birmingham
B15 2TG
United Kingdom
Birmingham
B4 6NH
United Kingdom
Newcastle upon Tyne
NE1 4LP
United Kingdom
Manchester
M13 9WL
United Kingdom
Middlesbrough
TS4 3BW
United Kingdom
Cardiff
CF14 4XW
United Kingdom
Lambeth
London
SE1 7EH
United Kingdom
Nottingham
NG5 1PB
United Kingdom
Burnley
BB10 2PQ
United Kingdom
Nottingham
NG7 2UH
United Kingdom
Sunderland
SR4 7TP
United Kingdom
Liverpool
L8 7SS
United Kingdom
Isleworth
TW7 6AF
United Kingdom
Norwich
NR4 7UY
United Kingdom
Fulwood
Preston
PR2 9HT
United Kingdom
Southampton
Southampton
SO16 5YA
United Kingdom
Apley
Telford
TF1 6TF
United Kingdom
Leeds
LS9 7TF
United Kingdom
Leeds
LS1 3EX
United Kingdom
Truro
TR1 3LQ
United Kingdom
Sponsor information
Hospital/treatment centre
Mindelsohn Way
Edgbaston
Birmingham
B15 2TG
England
United Kingdom
"ROR" |
https://ror.org/056ajev02 |
|---|
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- NIHR Health Technology Assessment Programme, HTA
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 31/05/2020 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Analysis and write up should be completed by June 2019 and will be disseminated accordingly: 1. Guidelines: The information is expected to be rapidly incorporated into guidelines by the RCOG, and NICE, and disseminated to maternity units for implementation. 2. Lay information resources: Production of lay information with links to appropriate maternity organisations, particularly the National Childbirth Trust (NCT) and the NHS Choices. Lay information will describe the circumstances for intervention, and the advantages of the higher oxytocin rate, if found beneficial. Results will be posted on the website and disseminated widely using social media. 3. Conferences: The findings will be presented and disseminated via the British Maternal Fetal Medicine Society(BMFMS), RCOG and other national and international conferences. Peer reviewed publications: The results of the trial will be published in a high impact peer reviewed Journal as an Open Access publication. We will disseminate the completed paper to the Department of Health, the Scientific Advisory Committees of the RCOG and the RCM. NIHR Journals Library: If funded, the NIHR Journals Library will help with dissemination of findings and will provide an important, permanent and comprehensive record of the study. 4. Media: In consultation with the investigators and appropriate journal, a press release will be issued to the media upon publication of the results. The pilot study has already been the subject of an interview on BBC Radio 4 'Woman's Hour'. 5. Education: via RCM CPD courses, and the Obstetrician and Gynaecologist (TOG) midwives and doctors will be updated. Results of the study will be shared with staff members at research sites and other related trials in the area and we will provide a generic results presentation. A formal notification to the ethics committee, MHRA, the manufacturing authorisation holder and sponsors will be made. Outreach to other key stakeholders (trial networks, health advocates) involved in related trials is planned. The trial team has key individuals to optimise the dissemination of results. The Chair of Intrapartum Care CSG (Sara Kenyon), the Honorary Secretary of the BMFMS (Tracey Johnston) and the Editor in Chief of The Obstetrician and Gynaecologist (TOG) (Jason Waugh), Associate Editor of Archives of Diseases in Childhood (Andy Ewer) and a NCT volunteer (Ruth Hewston) are all co-applicants. |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 20/09/2023 | No | No |
Editorial Notes
20/09/2023: A link to the HRA research summary was added.
04/09/2017: Individual patient data sharing statement has been added. The following have been added as trial participating sites: Birmingham Women and Children's Hospital, Royal Victoria Infirmary Newcastle, St Mary’s Hospital Manchester, James Cook, University Hospital of Wales, St Thomas’ Hospital London, Nottingham City Hospital, Burnley General Hospital, Queens Medical Centre Nottingham, Sunderland Royal Hospital, Liverpool Women’s Hospital, West Middlesex University Hospital, Norfolk and Norwich Hospital, Royal Preston, Princess Anne Hospital, Southampton, The Princess Royal Hospital, Telford, St James’s University Hospital Leeds, Leeds General Hospital, Royal Cornwall Hospital.
